Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HANDOK Inc. (002390.KS)
KRW8,120.00
+220.00 (+2.78%)
KR KSC Healthcare Medical - Pharmaceuticals
Address
132 Teheran-ro 6235
Seoul, KR
Seoul, KR
CEO
Cho Jae-cheon
Website
handok.co.kr
IPO
2000-01-04
ISIN KR7002390003
Description
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. In addition, the company engages in real estate leasing. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is headquartered in Seoul, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW8,120.00
+220.00 (+2.78%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
29.4K
Beta
0.24
Float Shares
7.35M
Free Float %
56.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.71% | -6.24% | -19.90% | -24.57% | -29.33% | -25.24% | -26.93% | -44.53% | -70.80% | -77.98% | +198.17% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
8,120.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.05
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+5.5% Q1'26: +13.0% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+95.7% ★ Q1'26: -17.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-4.9% Q1'26: -1.3% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+0.6% Q1'26: +0.6% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+0.5% Q1'26: +0.4% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: -5.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×14.16× Q1'26: 14.25× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
Dec 2032 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
358.45B
est: 371.40B (-3.5%)
|
396.13B
est: 400.50B (-1.1%)
|
417.97B
est: 422.80B (-1.1%)
|
446.73B
est: 430.70B (+3.7%)
|
473.00B
est: 464.55B (+1.8%)
|
503.61B
est: 497.20B (+1.3%)
|
517.64B
est: 506.90B (+2.1%)
|
543.76B
est: 523.20B (+3.9%)
|
522.74B
est: 536.00B (-2.5%)
|
535.14B
est: 422.80B (+26.6%)
|
422.80B
422.80B – 422.80B
+0.0% YoY
|
430.70B
430.70B – 430.70B
+1.9% YoY
|
464.55B
464.55B – 464.55B
+7.9% YoY
|
497.20B
497.20B – 497.20B
+7.0% YoY
|
506.90B
506.90B – 506.90B
+2.0% YoY
|
523.20B
523.20B – 523.20B
+3.2% YoY
|
536.00B
536.00B – 536.00B
+2.4% YoY
|
| EBITDA |
20.39B
est: 18.64B (+9.4%)
|
18.43B
est: 20.11B (-8.3%)
|
15.61B
est: 21.22B (-26.5%)
|
35.12B
est: 21.62B (+62.4%)
|
75.46B
est: 23.32B (+223.6%)
|
49.83B
est: 24.96B (+99.6%)
|
49.37B
est: 25.45B (+94.0%)
|
50.26B
est: 26.27B (+91.3%)
|
2.76B
est: 26.91B (-89.7%)
|
26.80B
est: 17.09B (+56.8%)
|
17.09B
17.09B – 17.09B
+0.0% YoY
|
17.41B
17.41B – 17.41B
+1.9% YoY
|
18.78B
18.78B – 18.78B
+7.9% YoY
|
20.10B
20.10B – 20.10B
+7.0% YoY
|
20.49B
20.49B – 20.49B
+2.0% YoY
|
21.15B
21.15B – 21.15B
+3.2% YoY
|
21.67B
21.67B – 21.67B
+2.4% YoY
|
| EBIT |
2.02B
est: 2.80B (-27.8%)
|
-6.68B
est: 3.02B (-321.1%)
|
12.33B
est: 3.19B (+286.7%)
|
15.21B
est: 3.25B (+368.3%)
|
53.78B
est: 3.50B (+1,435.4%)
|
48.89B
est: 3.75B (+1,204.1%)
|
10.53B
est: 3.82B (+175.6%)
|
15.54B
est: 3.94B (+294.0%)
|
-19.73B
est: 4.04B (-588.1%)
|
3.29B
est: -1.06B (+411.5%)
|
-1.06B
-1.06B – -1.06B
+0.0% YoY
|
-1.08B
-1.08B – -1.08B
-1.9% YoY
|
-1.16B
-1.16B – -1.16B
-7.9% YoY
|
-1.24B
-1.24B – -1.24B
-7.0% YoY
|
-1.27B
-1.27B – -1.27B
-2.0% YoY
|
-1.31B
-1.31B – -1.31B
-3.2% YoY
|
-1.34B
-1.34B – -1.34B
-2.4% YoY
|
| Net Income |
-1.69B
est: -4.67B (+63.8%)
|
-6.45B
est: 1.28B (-604.2%)
|
4.87B
est: -3.41B (+242.6%)
|
7.99B
est: 8.69B (-8.0%)
|
34.93B
est: 13.96B (+150.3%)
|
26.96B
est: 8.78B (+207.0%)
|
3.29B
est: 15.68B (-79.0%)
|
10.68B
est: 18.31B (-41.6%)
|
-28.80B
est: 21.58B (-233.4%)
|
-2.15B
est: -3.41B (+36.9%)
|
-3.41B
-3.41B – -3.41B
+0.0% YoY
|
8.69B
8.69B – 8.69B
+354.4% YoY
|
13.96B
13.96B – 13.96B
+60.7% YoY
|
8.78B
8.78B – 8.78B
-37.1% YoY
|
15.68B
15.68B – 15.68B
+78.5% YoY
|
18.31B
18.31B – 18.31B
+16.8% YoY
|
21.58B
21.58B – 21.58B
+17.9% YoY
|
| SGA |
49.97B
est: 41.91B (+19.2%)
|
55.89B
est: 45.20B (+23.7%)
|
57.53B
est: 47.71B (+20.6%)
|
57.53B
est: 48.61B (+18.4%)
|
59.80B
est: 52.43B (+14.1%)
|
56.07B
est: 56.11B (-0.1%)
|
54.34B
est: 57.20B (-5.0%)
|
57.53B
est: 59.04B (-2.6%)
|
60.80B
est: 60.49B (+0.5%)
|
61.83B
est: 48.07B (+28.6%)
|
48.07B
48.07B – 48.07B
+0.0% YoY
|
48.97B
48.97B – 48.97B
+1.9% YoY
|
52.82B
52.82B – 52.82B
+7.9% YoY
|
56.53B
56.53B – 56.53B
+7.0% YoY
|
57.63B
57.63B – 57.63B
+2.0% YoY
|
59.48B
59.48B – 59.48B
+3.2% YoY
|
60.94B
60.94B – 60.94B
+2.4% YoY
|
| EPS |
-136.00
est: -339.00 (+59.9%)
|
-518.49
est: 93.00 (-657.5%)
|
391.00
est: -248.00 (+257.7%)
|
590.00
est: 631.00 (-6.5%)
|
2,543.86
est: 1,014.00 (+150.9%)
|
1,957.92
est: 638.00 (+206.9%)
|
239.28
est: 1,139.00 (-79.0%)
|
775.88
est: 1,330.00 (-41.7%)
|
-2,091.39
est: 1,568.00 (-233.4%)
|
-162.61
est: -248.00 (+34.4%)
|
-248.00
-248.00 – -248.00
+0.0% YoY
|
631.00
631.00 – 631.00
+354.4% YoY
|
1,014.00
1,014.00 – 1,014.00
+60.7% YoY
|
638.00
638.00 – 638.00
-37.1% YoY
|
1,139.00
1,139.00 – 1,139.00
+78.5% YoY
|
1,330.00
1,330.00 – 1,330.00
+16.8% YoY
|
1,568.00
1,568.00 – 1,568.00
+17.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
11.53B
OE per share TTM
865.35
Owner's Yield
10.55%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
39.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 4 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.00% | 29.4K | 0.15% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 67.8K | 0.39% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 29.7K | 0.28% |
| 4 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 170.76 | 0.56% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.46M
Shares Outstanding
12.99M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeong-yol Cho | President | — | female |
| Jin Ki Baek | Vice President & Executive Director | — | — |
| Miyeon | President, Director & Chief Operating Officer | — | female |
| Young-Jin Kim | Chairman & Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002390.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
